Compare Abeona Therapeutics Inc (ABEO) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Orion Office REIT Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Orion Office REIT Inc trades at $2.8 (market cap $157.99M). The key difference: Abeona Therapeutics Inc is far larger — about 2.4× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 2.88% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ONL | |
|---|---|---|
Market Cap | $373.32M | $157.99M |
Sector | Health | Real Estate |
52-Week High | $7.23 | $3.04 |
52-Week Low | $4.17 | $1.93 |
Enterprise Value | $228.22M | $641.64M |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ONL trades at $2.78, down 1.77% on the day, with a neutral technical signal and bearish moving averages. The company shows a gross margin of 56.71% but deep net losses, with revenue declining from $208M in 2022 to $148M in 2025. Recent news highlights progress on leasing and strategic reviews, while cash flow remains positive but shrinking.
Outlook is cautious due to persistent losses and high debt, though strategic asset sales and refinancing reduce near-term risks. The 50% analyst buy rating offers some optimism, but investors face significant fundamental challenges amid the troubled office REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
